Table 1. Clones derived from CD8⁺ CD28⁺ CLA^high PBMC with HSV-2-specific CTL activity.

Subject	Clones screened	CTL clones*	Percent CTL clones
1	241	76	31.5
2	319	95	29.8
3	86	14	16.3
4	64	4	6.2
5	96	6	6.2
6	84	5	5.9
7	288	10	3.5
8	194	6	3.1
9	93	2	2.1
10	12	0	0
11†	58	0	0

^*Clones with >25% specific release for autologous HSV-2-infected B cell targets and <10% specific release for autologous uninfected targets.

^†Seronegative for HSV-1 and -2, control subject.